# OnCo record paper-turner-c-trak-tn-ctdna-pembrolizumab-ann-oncol-2023 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: .
@prefix onco: .
@prefix xsd: .
a schema:ScholarlyArticle ;
onco:kind "paper" ;
schema:identifier "paper-turner-c-trak-tn-ctdna-pembrolizumab-ann-oncol-2023" ;
schema:name "Results of the c-TRAK TN trial: a clinical trial utilising ctDNA mutation tracking to detect molecular residual disease and trigger intervention in patients with moderate- and high-risk early-stage triple-negative breast cancer"@en ;
schema:description "The UK trial that watched 161 women with early triple-negative breast cancer by three-monthly blood tests for tumour DNA: 27 percent tested positive within a year, but by then nearly three quarters already had visible metastases, and none of the five who started pembrolizumab cleared the DNA. The lesson was to test earlier and more sensitively."@en ;
schema:url ;
schema:dateModified "2026-09-24"^^xsd:date ;
schema:citation , , ;
onco:tag "tnbc-evidence" ;
schema:sameAs ;
schema:datePublished "2023"^^xsd:gYear ;
schema:author "Turner NC, Swift C, Jenkins B, et al." ;
onco:related , , ;
onco:cancers , ;
onco:technologies , , ;
onco:drugs ;
onco:institutions , , ;
onco:terms , , ;
onco:people ;
onco:bottlenecks , ;
onco:journals .